Lv2
110 积分 2024-05-15 加入
Mechanisms of Response and Tolerance to Active RAS Inhibition in KRAS-Mutant Non–Small Cell Lung Cancer
3天前
已完结
Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial
23天前
已完结
The recent advance of Interleukin-1 receptor associated kinase 4 inhibitors for the treatment of inflammation and related diseases
1个月前
已完结
Targeting cancer with small-molecule pan-KRAS degraders
1个月前
已完结
Selective degradation of multimeric proteins by TRIM21-based molecular glue and PROTAC degraders
1个月前
已完结
Recent insights of PROTAC developments in inflammation-mediated and autoimmune targets: a critical review
1个月前
已完结
PROTAC in clinic for autoimmune skin disease
1个月前
已完结
Discovery of Potent, Highly Selective, and Efficacious SMARCA2 Degraders
4个月前
已完结
Pharmacologic restoration of GTP hydrolysis by mutant RAS
4个月前
已完结
Measurement of KRAS-GTPase Activity
9个月前
已完结
皖公网安备34019202002308
